Tackling late HIV diagnosis: Lessons from the UK in the COVID-19 era.

"The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Marta Boffito received travel grants, speaker and advisor fees, and research grants to the organisation from Janssen, Roche, ViiV, Bristol Myers Squibb, Merck Sharp & Dohme, Gilead Sciences, Mylan, Cipla, Novavax, Valneva, GSK, Atea, Moderna, Teva, AZ and Pfizer. David R Chadwick is a trustee/executive member of the British HIV Association and has recently chaired a sub-group on guidelines for Emergency Department opt-out testing using implied consent. He has also received research grants from Gilead Sciences. Samuel Kabagambe is an employee of Gilead Sciences and may own stock options in Gilead Sciences. Bakita Kasadha has previously received speaker honoraria and consultancy fees from Gilead Sciences. Cindy Elliott is an employee of Gilead Sciences and may own stock options in Gilead Sciences. Emily Boardman, and Emily Cheserem declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article."

"Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Gilead Sciences, Inc., Foster City, CA, USA, provided funding for medical writing support."